大型III期临床研究及荟萃分析显示,合理应用新辅助治疗可以提高乳腺癌疗效,增加保留乳房的机会,也改变了乳腺癌首选手术治疗的单一传统治疗模式[1]。但是,新辅助治疗期间应及时评价疗效,以避免治疗无效病例丧失手术机会至关重要。本文报告笔者医院近期经治的2例新 Large phase III clinical studies and meta-analyzes show that rational use of neoadjuvant therapy can improve the efficacy of breast cancer, increase the chance of breast conserving, and change the single traditional treatment modality of choice for breast cancer [1]. However, neoadjuvant treatment should be evaluated in a timely manner to avoid invalid treatment ineffective cases of surgical opportunities is crucial. This article reports author’s hospital recently 2 cases of governance